AARD — Aardvark Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1774857 ·
Last close
$1.15
Market Cap
$25.17M
52W High
$16.60
52W Low
$0.93
ADV30
1,206,783
Next earnings
2026-11-13
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -19,717,000 -19,186,000 64,800,000 60,335,000 7,193,000
Jun 2026 0 — -15,084,000 -14,387,000 81,460,000 73,849,000 6,663,000
Mar 2026 0 — -22,464,000 -21,588,000 98,590,000 62,436,000 11,604,000
Dec 2025 0 — -18,704,000 -17,598,000 117,181,000 47,051,000 10,548,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-69,408,000
Investing CF
$116,548,000
Financing CF
$711,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.21
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-151,893,000
Inventory
—
Receivables
—
ST Investments
$21,000
EBIT TTM
$-73,955,000
Pretax Income TTM
$-69,889,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -62,725,000 -57,591,000 117,181,000 10,548,000 106,633,000 -54,172,000
Dec 2024 0 -22,668,000 -20,588,000 77,507,000 132,150,000 -54,643,000 -18,087,000
Dec 2023 0 -6,653,000 -7,208,000 10,536,000 45,338,000 -34,802,000 -5,824,000
Dec 2022 0 -10,874,000 -13,564,000 16,757,000 44,680,000 -27,923,000 -10,543,000

TTM Snapshot

Revenues TTM
$4,060,000
NetIncome TTM
$-69,889,000
OpCashFlow TTM
—
Assets (Latest)
$81,460,000
Forward EPS
$-2.34

Peers — same industry

TickerNameMarket CapLastDaily %
CLCS Cell Source, Inc. $25.14M $0.37 —
BIOE Bio Essence Corp $25.29M $0.47 —
ABVC ABVC BIOPHARMA, INC. $25.36M $0.94 —
BETRF BetterLife Pharma Inc. $25.64M $0.15 —
ACET Adicet Bio, Inc. $26.03M $2.78 —

News headlines (Yahoo Finance, 1h cache)

Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-13 13:00 · Yahoo
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
2026-10-23 11:00 · Yahoo
Aardvark Therapeutics stock surges as FDA lifts clinical hold
2026-10-22 21:57 · Yahoo
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
2026-10-22 20:05 · Yahoo
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
2026-10-21 15:00 · Yahoo
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
2026-10-12 14:31 · Yahoo
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
2026-10-08 12:00 · Yahoo
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
2026-08-17 17:31 · Yahoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
2026-05-28 10:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.